Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "precision-diagnostics"

16 News Found

SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’
News | November 23, 2022

SRL Diagnostics hosts ‘International Gynecologic & Breast Cancer Symposium 2022’

Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India


Thermo Fisher Scientific emphasizes on the need for more disruptive technologies
Medical Device | October 09, 2022

Thermo Fisher Scientific emphasizes on the need for more disruptive technologies

Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.


Crosscope and Farcast Biosciences join efforts to reshape the precision oncology landscape
Biotech | May 23, 2022

Crosscope and Farcast Biosciences join efforts to reshape the precision oncology landscape

The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements
Drug Approval | August 10, 2021

QIAGEN and OncXerna Therapeutics sign licensing and master companion diagnostic agreements

QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab